 Connection
Jeffrey Swigris to Disease Progression
This is a "connection" page, showing publications Jeffrey Swigris has written about Disease Progression.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
0.881 |
|
|
|
-
Kreuter M, Swigris J, Pittrow D, Geier S, Klotsche J, Prasse A, Wirtz H, Koschel D, Andreas S, Claussen M, Groh? C, Wilkens H, Hagmeyer L, Skowasch D, Meyer JF, Kirschner J, Gl?ser S, Kahn N, Welte T, Neurohr C, Schwaiblmair M, Held M, Bahmer T, Oqueka T, Frankenberger M, Behr J. The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. Respir Res. 2019 Mar 15; 20(1):59.
Score: 0.091
-
Ramadurai D, Corder S, Churney T, Graney B, Harshman A, Meadows S, Swigris JJ. Idiopathic pulmonary fibrosis: Educational needs of health-care providers, patients, and caregivers. Chron Respir Dis. 2019 Jan-Dec; 16:1479973119858961.
Score: 0.090
-
Swigris JJ, Brown KK, Abdulqawi R, Buch K, Dilling DF, Koschel D, Thavarajah K, Tomic R, Inoue Y. Patients' perceptions and patient-reported outcomes in progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018 Dec 31; 27(150).
Score: 0.090
-
Swigris J. Caution against Extrapolating Results from the Trial of Long-Term Oxygen for Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc. 2017 02; 14(2):296.
Score: 0.079
-
Albera C, Costabel U, Fagan EA, Glassberg MK, Gorina E, Lancaster L, Lederer DJ, Nathan SD, Spirig D, Swigris JJ. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016 09; 48(3):843-51.
Score: 0.076
-
Solomon JJ, Chung JH, Cosgrove GP, Demoruelle MK, Fernandez-Perez ER, Fischer A, Frankel SK, Hobbs SB, Huie TJ, Ketzer J, Mannina A, Olson AL, Russell G, Tsuchiya Y, Yunt ZX, Zelarney PT, Brown KK, Swigris JJ. Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J. 2016 Feb; 47(2):588-96.
Score: 0.073
-
Swigris JJ, Lee HS, Cohen M, Inoue Y, Moss J, Singer LG, Young LR, McCormack FX. St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis. Chest. 2013 Jun; 143(6):1671-1678.
Score: 0.061
-
Swigris JJ, Brown KK. Acute interstitial pneumonia and acute exacerbations of idiopathic pulmonary fibrosis. Semin Respir Crit Care Med. 2006 Dec; 27(6):659-67.
Score: 0.039
-
Swigris JJ, Stewart AL, Gould MK, Wilson SR. Patients' perspectives on how idiopathic pulmonary fibrosis affects the quality of their lives. Health Qual Life Outcomes. 2005 Oct 07; 3:61.
Score: 0.036
-
Swigris JJ, Gould MK, Wilson SR. Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest. 2005 Jan; 127(1):284-94.
Score: 0.034
-
Humphries SM, Adegunsoye A, Demoruelle MK, Wei Kam ML, Amigues I, Bang TJ, Teague SD, Lynch DA, Chung JH, Strek ME, Swigris JJ, Solomon JJ. Quantitative CT Scan Analysis in Rheumatoid Arthritis-Related Interstitial Lung Disease. Chest. 2025 May; 167(5):1428-1439.
Score: 0.034
-
Wijsenbeek M, Swigris JJ, Inoue Y, Kreuter M, Maher TM, Suda T, Baldwin M, Mueller H, Rohr KB, Flaherty KR. Effects of nintedanib on symptoms in patients with progressive pulmonary fibrosis. Eur Respir J. 2024 Feb; 63(2).
Score: 0.032
-
Fern?ndez P?rez ER, Crooks JL, Lynch DA, Humphries SM, Koelsch TL, Swigris JJ, Solomon JJ, Mohning MP, Groshong SD, Fier K. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax. 2023 11; 78(11):1097-1104.
Score: 0.030
-
Chartrand S, Lee JS, Swigris JJ, Stanchev L, Fischer A. Clinical Characteristics and Natural History of Autoimmune Forms of Interstitial Lung Disease: A Single-Center Experience. Lung. 2019 12; 197(6):709-713.
Score: 0.024
-
Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, Brown CE, Calligaro G, Cassidy N, Corte TJ, Geissler K, Hassan AA, Johannson KA, Kairalla R, Kolb M, Kondoh Y, Quadrelli S, Swigris J, Udwadia Z, Wells A, Wijsenbeek M. Palliative care in interstitial lung disease: living well. Lancet Respir Med. 2017 12; 5(12):968-980.
Score: 0.021
-
Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, Goldin J, Arriola E, Volkmann ER, Kafaja S, Silver R, Steen V, Strange C, Wise R, Wigley F, Mayes M, Riley DJ, Hussain S, Assassi S, Hsu VM, Patel B, Phillips K, Martinez F, Golden J, Connolly MK, Varga J, Dematte J, Hinchcliff ME, Fischer A, Swigris J, Meehan R, Theodore A, Simms R, Volkov S, Schraufnagel DE, Scholand MB, Frech T, Molitor JA, Highland K, Read CA, Fritzler MJ, Kim GHJ, Tseng CH, Elashoff RM. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. Lancet Respir Med. 2016 09; 4(9):708-719.
Score: 0.019
-
Nathan SD, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Glasscock KF, King TE, Lancaster L, Lederer DJ, Lin Z, Pereira CA, Swigris JJ, Valeyre D, Noble PW, Wells AU. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016 05; 71(5):429-35.
Score: 0.019
-
Noble PW, Albera C, Bradford WZ, Costabel U, du Bois RM, Fagan EA, Fishman RS, Glaspole I, Glassberg MK, Lancaster L, Lederer DJ, Leff JA, Nathan SD, Pereira CA, Swigris JJ, Valeyre D, King TE. Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials. Eur Respir J. 2016 Jan; 47(1):243-53.
Score: 0.018
-
King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29; 370(22):2083-92.
Score: 0.016
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|